Literature DB >> 32551007

Computer-Aided Fragment Growing Strategies to Design Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase.

Lena Hefke1, Kerstin Hiesinger1, W Felix Zhu1, Jan S Kramer1, Ewgenij Proschak1.   

Abstract

Multitarget ligands are interesting candidates for drug discovery and development due to improved safety and efficacy. However, rational design and optimization of multitarget ligands is tedious because affinity optimization for two or more targets has to be performed simultaneously. In this study, we demonstrate that, given a molecular fragment, which binds to two targets of interest, computer-aided fragment growing can be applied to optimize compound potency, relying on either ligand- or structure-derived information. This methodology is applied to the design of dual inhibitors of soluble epoxide hydrolase and leukotriene A4 hydrolase.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32551007      PMCID: PMC7294724          DOI: 10.1021/acsmedchemlett.0c00102

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  32 in total

Review 1.  From magic bullets to designed multiple ligands.

Authors:  Richard Morphy; Corinne Kay; Zoran Rankovic
Journal:  Drug Discov Today       Date:  2004-08-01       Impact factor: 7.851

Review 2.  Designed multiple ligands. An emerging drug discovery paradigm.

Authors:  Richard Morphy; Zoran Rankovic
Journal:  J Med Chem       Date:  2005-10-20       Impact factor: 7.446

Review 3.  Fragments, network biology and designing multiple ligands.

Authors:  Richard Morphy; Zoran Rankovic
Journal:  Drug Discov Today       Date:  2006-12-14       Impact factor: 7.851

Review 4.  Molecular fingerprint similarity search in virtual screening.

Authors:  Adrià Cereto-Massagué; María José Ojeda; Cristina Valls; Miquel Mulero; Santiago Garcia-Vallvé; Gerard Pujadas
Journal:  Methods       Date:  2014-08-15       Impact factor: 3.608

5.  PENG: a neural gas-based approach for pharmacophore elucidation. method design, validation, and virtual screening for novel ligands of LTA4H.

Authors:  Daniel Moser; Sandra K Wittmann; Jan Kramer; René Blöcher; Janosch Achenbach; Denys Pogoryelov; Ewgenij Proschak
Journal:  J Chem Inf Model       Date:  2015-02-09       Impact factor: 4.956

6.  Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor.

Authors:  Chao Zhang; Prabha N Ibrahim; Jiazhong Zhang; Elizabeth A Burton; Gaston Habets; Ying Zhang; Ben Powell; Brian L West; Bernice Matusow; Garson Tsang; Rafe Shellooe; Heidi Carias; Hoa Nguyen; Adhirai Marimuthu; Kam Y J Zhang; Angela Oh; Ryan Bremer; Clarence R Hurt; Dean R Artis; Guoxian Wu; Marika Nespi; Wayne Spevak; Paul Lin; Keith Nolop; Peter Hirth; Greg H Tesch; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

7.  Thermodynamic properties of leukotriene A4 hydrolase inhibitors.

Authors:  Sandra K Wittmann; Lena Kalinowsky; Jan S Kramer; René Bloecher; Stefan Knapp; Dieter Steinhilber; Denys Pogoryelov; Ewgenij Proschak; Jan Heering
Journal:  Bioorg Med Chem       Date:  2016-08-26       Impact factor: 3.641

8.  Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.

Authors:  Dean R Artis; Jack J Lin; Chao Zhang; Weiru Wang; Upasana Mehra; Mylene Perreault; David Erbe; Heike I Krupka; Bruce P England; James Arnold; Alexander N Plotnikov; Adhirai Marimuthu; Hoa Nguyen; Sarah Will; Maxime Signaevsky; John Kral; John Cantwell; Calvin Settachatgull; Douglas S Yan; Daniel Fong; Angela Oh; Shenghua Shi; Patrick Womack; Benjamin Powell; Gaston Habets; Brian L West; Kam Y J Zhang; Michael V Milburn; George P Vlasuk; K Peter Hirth; Keith Nolop; Gideon Bollag; Prabha N Ibrahim; James F Tobin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-30       Impact factor: 11.205

9.  Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase.

Authors:  Thomas A Kirkland; Marc Adler; John G Bauman; Ming Chen; Jesper Z Haeggström; Beverly King; Monica J Kochanny; Amy M Liang; Lisa Mendoza; Gary B Phillips; Marjolein Thunnissen; Lan Trinh; Marc Whitlow; Bin Ye; Hong Ye; John Parkinson; William J Guilford
Journal:  Bioorg Med Chem       Date:  2008-03-20       Impact factor: 3.641

Review 10.  Leukotriene biosynthetic enzymes as therapeutic targets.

Authors:  Jesper Z Haeggström
Journal:  J Clin Invest       Date:  2018-07-02       Impact factor: 14.808

View more
  4 in total

1.  Mitochondria Are Potential Targets for the Development of New Drugs Against Neutrophilic Inflammation in Severe Pneumonia Including COVID-19.

Authors:  Nina V Vorobjeva; Galina F Sud'ina; Boris V Chernyak
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

Review 2.  Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer.

Authors:  Amarjyoti Das Mahapatra; Rinku Choubey; Bhaskar Datta
Journal:  Molecules       Date:  2020-11-24       Impact factor: 4.411

Review 3.  Fragment-to-Lead Medicinal Chemistry Publications in 2020.

Authors:  Iwan J P de Esch; Daniel A Erlanson; Wolfgang Jahnke; Christopher N Johnson; Louise Walsh
Journal:  J Med Chem       Date:  2021-12-20       Impact factor: 7.446

Review 4.  Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products.

Authors:  Cheng-Peng Sun; Xin-Yue Zhang; Christophe Morisseau; Sung Hee Hwang; Zhan-Jun Zhang; Bruce D Hammock; Xiao-Chi Ma
Journal:  J Med Chem       Date:  2020-12-28       Impact factor: 7.446

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.